COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Centers for Disease Control and Prevention is tracking COVID-19 vaccinations through its COVID Data Tracker, validating the numbers with jurisdictions through the data submission process, CDC announced.
The Food and Drug Administration alerted clinical laboratories and health care providers of its ongoing effort to monitor the potential molecular test impact resulting from SARS-CoV-2 mutations, including the B.1.1.7 variant that has emerged from the United Kingdom.
The Centers for Disease Control and Prevention allocated $22 billion in funding to states, localities and territories for COVID-19 testing and vaccination activities authorized in December by the Coronavirus Response and Relief Supplemental Appropriations Act.
The Centers for Medicare & Medicaid Services released updated guidance in response to questions on maintaining Medicaid enrollment during the Public Health Emergency under its interim final rule implementing Section 6008 of the Families First Coronavirus Response Act.
The Food and Drug Administration warned that Curative’s SARS-Cov-2 test could produce false results and that health care providers should strictly follow its authorization and labeling.
The Food and Drug Administration reminded the public of the importance of receiving COVID-19 vaccines in accordance to their agency authorizations, a process that FDA said will safely provide the “remarkable” levels of protection observed during large, randomized clinical trials.
The Food and Drug Administration last month added to its device shortage list several device types, along with clarifying notes and resource links.
Details on dosing, storage and preparation of Moderna’s mRNA-1273 COVID-19 vaccine.
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee Dec. 17 recommended the approval of Moderna’s mRNA-1273 COVID-19 vaccine candidate.
The Centers for Medicare & Medicaid Services announced that it is extending the third quarter 2020 data submission deadlines for several of its quality reporting and value programs for hospitals, post-acute care and other providers.